P. Needham

发表

The selective dopamine antagonist properties of BRL 34778: a novel substituted benzamide

G. Riley, M. Clark, P. Mitchell, 2004, Psychopharmacology.

A comparison of the acute effects of zotepine and other antipsychotics on rat cortical dopamine release, in vivo

I. Kilpatrick, D. Heal, H. Rowley, 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.

Chronic, but not acute, dosing of antipsychotic drugs alters neurotensin binding in rat brain regions

S. Aspley, P. Needham, P. E. Holtom, 2000, British journal of pharmacology.

A highly sensitive and selective radioimmunoassay for the measurement of neurotensin

S. Aspley, G. W. Bennett, P. Needham, 2000, Journal of Neuroscience Methods.

Further Evidence that Behavioral Tests and Neuropeptide mRNA and Tissue Level Alterations Can Differentiate between Typical and Atypical Antipsychotic Drugs

I. Kilpatrick, W. Fleischhacker, J. Marksteiner, 2000, Neuropsychopharmacology.

Elevation of extracellular cortical noradrenaline may contribute to the antidepressant activity of zotepine: an in vivo microdialysis study in freely moving rats

I. Kilpatrick, D. Heal, H. Rowley, 1998, Neuropharmacology.

P-4-15 Zotepine: Preclinical tests predict antipsychotic efficacy and an atypical profile

D. Heal, P. Needham, M. Skill, 1995, European Neuropsychopharmacology.

Neurotensin: Controversial findings on its neuromodulatory role in the mesolimbic dopamine system

S. Aspley, P. Needham, P. E. Holtom, 2000, Schizophrenia Research.

BRL 20596, a novel anilide with central dopamine antagonist activity

M. Clark, P. Mitchell, W. Campbell, 2004, Psychopharmacology.

N-Substituted (2,3-dihydro-1,4-benzodioxin-2-yl)methylamine derivatives as D(2) antagonists/5-HT(1A) partial agonists with potential as atypical antipsychotic agents.

P. A. Bradley, F. Kerrigan, A. Birch, 1999, Journal of medicinal chemistry.